1 New-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I, DPP4I 2 and GLP1a: A population-based cohort study Oscar Hou In Chou MSc ^{1*}, Lei Lu, Ph.D. ^{2*}, Cheuk To Chung ³, Jeffrey Shi Kai Chan 3 MBChB MPH³, Raymond Ngai Chiu Chan MBChB³, Athena Lee Yan Hiu³, Edward 4 Christopher Dee MD ⁴, Kenrick Ng MB BChir MA MRCP PhD ^{5,6}, Hugo Hok Him Pui ³, 5 Sharen Lee MBChB³, Bernard Man Yung Cheung MB BChir PhD FRCP¹, Gary Tse MD 6 PhD FRCP ^{7, 8, 9}, Jiandong Zhou PhD ¹⁰ 7 8 9 ¹ Division of Clinical Pharmacology, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China 10 11 ² Institute of Biomedical Engineering, Department of Engineering Science, University of 12 Oxford, Oxford, United Kingdom 13 ³ Cardiovascular Analytics Group, Laboratory of Cardiovascular Physiology, Hong Kong, 14 China ⁴ Department of Radiation Oncology, Memorial Sloan Kettering Cancer, New York, United 15 16 States 17 ⁵ Department of Medical Oncology, University College London Hospital, London, UK. ⁶ Department of Medical Oncology, St Bartholomew's Hospital, London, UK 18 19 ⁷ School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, 20 China ⁸ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department 21 22 of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical 23 University, Tianjin 300211, China 24 ⁹ Kent and Medway Medical School, Canterbury Christ Church University and University of 25 Kent, Canterbury, United Kingdom 26 ¹⁰ Division of Experimental Medicine, Nuffield Department of Medicine, University of 27 Oxford, Oxford, United Kingdom 28 29 30 * Co-first author 31 32 ^ Correspondence to: 33 Jiandong Zhou, Ph.D. Division of Experimental Medicine, Nuffield Department of Medicine, University of Oxford, 34 35 Oxford, United Kingdom 36 Email: jiandong.zhou@ndm.ox.ac.uk 37 38


40 **Abstract** 41 **Background:** Sodium-glucose cotransporter 2 inhibitors (SGLT2I) have been suggested to 42 reduce new-onset cancer amongst type-2 diabetes mellitus (T2DM) patients. 43 **Objective:** This real-world study aims to compare the risks of prostate cancer between 44 SGLT2I and dipeptidyl peptidase-4 inhibitors (DPP4I) amongst T2DM patients. 45 **Design, setting and participants:** This was a retrospective population-based cohort study of 46 prospectively recorded data on type-2 diabetes mellitus (T2DM) male patients prescribed either SGLT2I or DPP4I between January 1st 2015 and December 31st 2020 from Hong 47 48 Kong. 49 **Methods:** The primary outcome was new-onset prostate cancer. The secondary outcomes 50 included cancer-related mortality and all-cause mortality. Propensity score matching (1:1 51 ratio) using the nearest neighbour search was performed and multivariable Cox regression 52 was applied to compare the risk. A three-arm sensitivity analysis including the glucagon-like 53 peptide-1 receptor agonist (GLP1a) cohort was conducted. 54 Results: This study included 42129 male T2DM patients (median age: 61.0 years old [SD: 12.2]; SGLT2I: n=17120; DPP4I: n=25009). After matching, the number of prostate cancers 55 56 was significantly lower in SGLT2I users (n = 60) than in DPP4I (n = 102). SGLT2I use was associated with lower prostate cancer risks (HR: 0.45; 95% CI: 0.30-0.70) after adjustments 57 58 than DPP4I. The results remained consistent in the sensitivity analysis. SGLT2I reduced the 59 risks of prostate cancer prominently amongst patients who were older (age >65), patients 60 with 2nd and 3rd quartile of HbA1c, concurrent metformin uses, and concurrent sulphonylurea 61 uses. SGLT2I was associated with higher risks of prostate cancer amongst sulphonylurea

62

non-users.

- 63 Conclusion: The real-world study demonstrated SGLT2I was associated with lower risks of
- 64 new-onset prostate cancer after matching and adjustments compared to DPP4I. This result
- warrants further prospective studies. 65

- 67 **Keywords:** Sodium-glucose cotransporter 2 inhibitors; Dipeptidyl peptidase-4 inhibitors;
- 68 Glucagon-like peptide-1 receptor agonist; Prostate; Prostate cancer



Graphical abstract

71

Introduction

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

cohort of T2DM patients from Hong Kong.

Type 2 diabetes mellitus (T2DM) and prostate cancer are two of the most common chronic diseases that are affected by the ageing male population [1, 2]. Despite relatively lower rates of prostate cancer in Asia compared to Northern America, there have been increasing incidence rates in several Asian countries, which is potentially related to the rising prevalence of obesity, metabolic aberrations and T2DM [3, 4]. The current literature suggests an association between T2DM and cancer proliferation, however its influence on the development of prostate cancer remains controversial [5]. This notwithstanding, there is also evidence suggesting that SGLT2I demonstrate a protective effect against new-onset overall cancer compared to DPP4I [6]. This has sparked interest in inquiring whether better diabetic management can reduce the risk of prostate cancer via existing anti-diabetic medications. Subsequently, this may allow clinicians to consider alternative treatment options for those at risk of prostate cancer. Previous results regarding the association of prostate cancer and metformin use remains controversial [7-10]. This further propagated research on novel anti-diabetic agents such as sodium-glucose cotransporter 2 inhibitors (SGLT2I) and dipeptidyl peptidase 4 inhibitors (DPP4I) on prostate cancer; as these drugs are the novel second line anti-diabetic medication commonly prescribed in Hong Kong and other developed countries. Previous studies has shown that the inhibition of SGLT2-mediated glucose uptake could reduce the proliferation of prostate cells molecularly [11]. Meanwhile, the clinical data on SGLT2I remained scarce. For direct comparison between the SGLT2I and DPP4I usage in the clinical setting, a study found no significant difference in risk of prostate cancer [12]. As of now, there is limited clinical evidence surrounding the association of SGLT2I and DPP4I on prostate cancer. This present study aims to investigate the role of SGLT2I and DPP4I with new-onset prostate cancer in a Methods

Study population

This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKWC IRB) (UW-20-250) and complied with the Declaration of Helsinki. This was a retrospective population-based study of prospectively collected electronic health records using the Clinical Data Analysis and Reporting System (CDARS) by the Hospital Authority (HA) of Hong Kong. The records cover both public hospitals and private clinics in Hong Kong. It was verified that over 90% of the identified T2DM patients were under the HA [13, 14]. This system has been used extensively by our teams and other research teams in Hong Kong. The system contains data on disease diagnosis, laboratory results, past comorbidities, clinical characteristics, and medication prescriptions. The system has been used by our Hong Kong research team to perform comparative studies [9, 15, 16]. T2DM patients who were administered with SGLT2I or DPP4I in centres under the Hong Kong HA, between January 1st, 2015, to December 31st, 2020, were included. The glucagon-like peptide-1 receptor agonist (GLP1a) cohort was included for sensitivity analysis to demonstrate the relative effects amongst the second line oral anti-diabetic agents.

Predictors and variables

Patients' demographics include gender and age of initial drug use (baseline), clinical and biochemical data were extracted for the present study. Prior comorbidities were extracted in accordance with the *International Classification of Diseases Ninth Edition* (ICD-9) codes (Supplementary Table 1). The diabetes duration was calculated by examining the earliest date

amongst the first date of (1) diagnosis using of ICD-9; (2) Hba1c >=6.5%; (3) Fasting glucose >= 7.0 mmol/l or Random glucose 11.1 mmol/l 4) Using anti-diabetic medications. The number of hospitalisations in the year prior the index days were extracted. The Charlson's standard comorbidity index was calculated [17]. The prostate medication (alpha-blockers), cardiovascular medications, anti-diabetic agents, and were extracted from the database. The duration and frequency of SGLT2I and DPP4I usage were calculated. The baseline laboratory examinations, including the glucose profiles and renal function tests were extracted. The microbiology testing results were also extracted to define the urinary tract infection (Supplementary Table 1). The estimated glomerular filtration rate (eGFR) was calculated using the abbreviated modification of diet in renal disease (MDRD) formula [18]. The following patient groups were excluded: those who (1) with prior prostate cancer (n=135); (2) died within 30 days after initial drug exposure (n=167); (3) without complete demographics (n=11); (4) under 18 years old (n=29); (5) new onset prostate cancer development less than 1 year after drug exposure (n=20) (Figure 1). To account for the incomplete laboratory data, the multiple imputation by chained equations was performed according to the previous published study [19].

Study outcomes

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

The primary outcome of this study was new-onset prostate cancer (ICD9: 185) after the index date of the drug use. The secondary outcomes were cancer-related mortality and all-cause mortality. Mortality data were obtained from the Hong Kong Death Registry, a population-based official government registry with the registered death records of all Hong Kong citizens linked to CDARS. Mortality was recorded using the *International Classification of Diseases Tenth Edition* (ICD-10) coding. The as-treat approach was adopted which patients were censored at treatment discontinuation or switching of the comparison medications. The

endpoint date of interest for eligible patients was the event presentation date. The endpoint for those without primary outcome was the mortality date or the end of the study period (31st December 2020).

Statistical analysis

Descriptive statistics are used to summarize baseline clinical and biochemical characteristics of patients with SGLT2I and DPP4I use. For baseline clinical characteristics, continuous variables were presented as mean (95% confidence interval/standard deviation [SD]) and the categorical variables were presented as total numbers (percentage). Propensity score matching generated by logistic regression with 1:1 ratio for SGLT2I use versus DPP4I use based on demographics, number of prior hospitalization, non-SGLT2I/DPP4I medications, number of prior anti-diabetic drugs, prior comorbidities, renal function, duration from T2DM diagnosis initial drug exposure, HbA1c and fasting glucose were performed using the nearest neighbour search strategy with a calliper of 0.1. Propensity score matching was performed using Stata software (Version 16.0). Baseline characteristics between patients with SGLT2I and DPP4I use before and after matching were compared with absolute standardized mean difference (SMD), with SMD<0.10 regarded as well-balanced between the two groups.

The cumulative incidence curves for the primary outcomes and secondary outcomes were constructed. Proportional Cox regression models were used to identify significant risk predictors of adverse study outcomes, with adjustment for demographics, comorbidities, number of prior hospitalisations, medication profile, renal function, glycaemic tests, and the duration of T2DM. The log-log plot was used to verify the proportionality assumption for the proportional Cox regression models. Subgroup analysis was conducted to confirm the association amongst patients with different clinical important predictors accounting to the diabetic and the metabolic profile, as well as the conditions and medications associated with

prostate diseases. Cause-specific and sub-distribution hazard models were conducted to consider possible competing risks. Multiple propensity adjustment approaches were used, including propensity score stratification [20], propensity score matching with inverse probability of treatment weighting [21] and propensity score matching with stable inverse probability weighting [22]. The three arm sensitivity results involving glucagon-like peptide-1 receptor agonist (GLP1a) using stabilized IPTW were conducted to test the association and choice amongst the novel second-line anti-diabetic medications. Patients with CKD stage 4/5 (eGFR <30 mL/min/1.73m²), peritoneal dialysis or haemodialysis who may be contraindicated with SGLT2I were excluded in the sensitivity analysis. Sensitivity analysis results with consideration of one-year lag time effects was also conducted. The hazard ratio (HR), 95% CI and P-value were reported. Statistical significance was defined as P-value < 0.05. All statistical analyses were performed with RStudio (Version: 1.1.456) and Python (Version: 3.6), unless otherwise specified.

Results

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

Basic characteristics

In this territory-wide cohort study of 42491 male patients with T2DM treated with SGLT2I or DPP4I between 1st January 2015 and 31st December 2020 in Hong Kong, patients were followed up until 31st December 2020 or until their deaths (Figure 1). After exclusion, This cohort comprises 42129 male T2DM patients with a mean age of 61.0 years old (Standard deviation: 12.2), amongst which 17120 patients used SGLT2Is, and 25009 patients used DPP4Is.

The DPP4I and SGLT2I cohorts were comparable after matching with nearest neighbour search strategy with calliper of 0.1, and the proportional hazard assumption was confirmed (Supplementary Figure 1). After the propensity score matching, the baseline characteristic of the SGLT2I and the DPP4I users were well-balanced, apart from sulphonylurea (SMD=0.17) and thiozolidinedone (SMD=0.11) (Table 1). The 2 unbalanced variables were adjusted in the Cox regression models and were included in the subgroup analysis. In the matched cohort, 162 patients (0.47%) developed new onset prostate cancer. The characteristics of patients are shown in Table 1.

Primary analysis

In the matched cohort, 60 SGLT2I users and 102 DPP4I users developed prostate cancer. In a total of 186869.4 person-year after a follow-up of a median of 5.61 years, the incidence of prostate cancer was lower amongst SGLT2I users (Incidence rate, IR: 0.63; 95% confidence interval, CI: 0. 48-0.81) than in DPP4I (IR: 1.11; CI: 0.90-1.34) users. SGLT2 inhibitors users had a 55% lower risk of prostate cancer compared to users of DPP-4 inhibitors after adjustment for demographics, comorbidities, number of prior hospitalisations, medication profile, renal function, glycaemic tests, and the duration of T2DM (HR: 0.45; 95% CI: 0.30-0.70, p=0.0003) (Table 2; Figure 2; Supplementary Table 2). This was substantiated by the cumulative incidence curves stratified by SGLT2I versus DPP4I (Figure 2). The marginal effects plots demonstrated that SGLT2I was associated with lower risks of prostate cancer regardless of the duration of the diabetes diagnosis (Supplementary Figure 2), regardless of the number of prior hospitalizations (Supplementary Figure 3).

In a total of 187191.9 person-year, 260 DPP4I and 99 SGLT2I users passed away due to cancer. The incidence of cancer-related mortality was lower amongst SGLT2I users (IR: 1.04; 95% CI: 0.85-1.27) compared to DPP4I users (IR: 2.81; 95% CI: 2.48-3.18). SGLT2I users had a 43% lower risk of cancer-related mortality after adjustment (HR: 0.55; 95% CI: 0.50-0.61, p<0.0001) compared to users of DPP4I. Besides, 1652 DPP4I users and 541 SGLT2I

users passed away. SGLT2I users had a 32% lower risk of all-cause mortality after adjustment (HR: 0.68; 95% CI: 0.46-0.78, p<0.0001) compared to users of DPP4I (**Table 2; Figure 2; Supplementary Table 2**).

Subgroup analysis and sensitivity analysis

The results of the subgroup analysis for the effects of SGLT2I and DPP4I on prostate cancer are shown in **Figure 3**. In the subgroup analysis, the results demonstrated that SGLT2I was associated with lower risks of prostate cancer amongst patients who were older (age >65). The results were consistent amongst patients with quartile 2 and 3 HbA1c. Besides, SGLT2I was associated with lower risks of prostate cancer amongst patients without prior heart failure, acute myocardial infarction, atrial fibrillation, peripheral vascular disease, cancer, and renal disease (all p<0.05). Furthermore, SGLT2I had lower risks of prostate cancer amongst patients without using alpha-blockers and antiplatelet (all p<0.05). SGLT2I was also associated with lower risks of prostate cancers amongst patients not on insulin, thiazolidinedione, GLP1a. However, those could be due to the insufficient sample size in the subgroups amongst the patients with the diseases or drug users. SGLT2I was also associated with lower risks of prostate cancer amongst metformin and sulphonylurea users. Indeed, SGLT2I was associated with higher risks of prostate cancer amongst patients without sulphonylurea (HR: 5.55; 95% CI: 1.26-22.43).

Sensitivity analysis

Sensitivity analyses were performed to confirm the predictability of the models. The results of the cause-specific hazard models, sub-distribution hazard models and different propensity score approaches demonstrated that different models do not change the point

Table 3). A 3-arm analysis with the inclusion of GLP1a including patients only on SGLT2I, DPP4I, and GLP1a using stabilized IPTW was conducted (Supplementary Table 4). The results between DPP4I and SGLT2I remained consistent with the main result (all p<0.05) (Table 2). However, it was found that SGLT2I was not associated with lower risks of prostate cancer compared to GLP1a. Excluding patients with CKD stage 4/5 (eGFR <30 mL/min/1.73m^2), peritoneal dialysis or haemodialysis in the matched cohort likewise demonstrated that SGLT2I was associated with lower risks of prostate cancer compared to DPP4I (Supplementary Table 5). Meanwhile, the sensitivity analysis for 1-year lag time also demonstrated the same trend (all p<0.05) (Supplementary Table 6).

Discussion

In this territory-wide cohort study, we utilised real-world data to compare the association between SGLT2I, DPP4I and new-onset prostate cancer. Our results suggest that SGLT2I usage is associated with a lowered risk of new-onset prostate cancer than DPP4I usage. To the best of our knowledge, this is the first study to directly compare the relative association of two anti-diabetic medications on the incidence of prostate cancer.

Comparison with previous studies

The prevalence of prostate cancer in our study (IR: 86.7; 95% CI: 73.9-101 per 100,000 person-year) is like the existing literature, which described an incidence of 65.1 per 100,000 person-year amongst T2DM patients in the whole China [23-25]. It was believed that T2DM patients are associated with an increased prevalence of prostate cancer and adverse complications [26]. A meta-analysis suggests that diabetic patients are associated with a worse

prognosis [27]. On the contrary, some studies show no correlation or even an inverse association between T2DM and prostate cancer [28]. While the relationship between T2DM and prostate cancer remained controversial, the pleiotropic effects of the anti-diabetic drugs may provide us with new insights.

In our study, we found that SGLT2I users had 55% relatively lower risks of prostate cancer compared to DPP4I users. In a previous meta-analysis, it was demonstrated that there was no association between SGLT2I use and incidence of overall cancer [29]. A meta-analysis found that DPP4I and SGLT2I show no significant association with prostate cancer compared to placebo, while GLP1a agents demonstrated beneficial effects against prostate cancer [30]. However, the 7 randomised control trials studies included regarding of SGLT2I were posthoc analyses without the primary aim of investigating prostate cancer, and the results demonstrated a relatively high heterogenicity ($P_{heterogenity} < 0.01$, $I^2 = 97.3\%$). The meta-analysis did not directly compare the effects between SGLT2I and DPP4I. For the SGLT2I-DPP4I comparison, Rokszin *et al.* found no significant difference in the risk of prostate cancer (HR: 0.65; 95% CI: 0.42-1.02) between the SGLT2I and DPP4I users [12]. However, the difference between the two arms remained worthy of investigation since the upper 95% CI of prostate cancer was close to 1 and that study followed up the patients for two years only, while in our study the follow-up duration median was 5.61 years.

The investigation of novel anti-diabetic medications was prompted by biological evidence in the current literature that underscores possible pleiotropic effects of SGLT2I and DPP4I on prostate cancer [31-33]. Interest in this area was prompted largely due to the fact that cancer cells utilise glucose as a primary source of fuel rather than fatty acids [34]. Moreover, evidence suggests that SGLT2I usage may inhibit the AMPK/mTOR pathway and induce apoptosis of cancerous cells [35]. Scafoglio *et al.* found abundant functional expression of SGLT2 on prostate adenocarcinomas; thereby inhibition of SGLT2 receptors reduces glucose

uptake and tumour progression in a xenograft model [36]. In a cell culture study, it was found that SGLT2I inhibited the clonogenic survival of prostate cancer cells [37]. In our study, the protective effects of SGLT2I were significant amongst patients without comorbidities but not those with prior comorbidities (heart failure, prior acute myocardial infarction, atrial fibrillation, peripheral vascular diseases). On one hand, while this could be explained by the limited sample size in the subgroups, we may also hypothesise that this could be explained partially by the SGLT2 expression level, as systemic diseases were suggested to increase the expression and activity of SGLT2 [38].

It must be noted that this does not necessarily mean that DPP4I is harmful in terms of new-onset prostate cancer, but it may as well be protective against prostate cancer compared to non-users. DPP4I and SGLT2I may modulate the risks of developing prostate cancer amongst T2DM patients. For DPP4I, previously, it was found that the use of saxagliptin and exenatide may decrease prostate cancer risk compared to sulfonylurea usage [39]. In another observational study, sitagliptin usage was associated with lower risks of prostate cancer amongst Asians with an odd ratio of 0.61 [40]. In addition, the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial revealed that malignant prostate neoplasms were present in a lower proportion of diabetic patients who use liraglutide compared to the placebo group [41]. Although the mechanism behind the observed effects of cancer growth inhibition remains ambiguous, the potential implications of SGLT2I and DPP4I usage as a part of cancer treatment continue to be revised in the growing body of literature.

Clinical implications

The potential antineoplastic benefit of SGLT2I and DPP4I on various cancer types have received global interest in recent years. As prostate cancer is one of the leading causes of cancer-related mortality among men, our findings could carry critical clinical implications in optimising treatment for T2DM male patients who might be at higher risk of developing prostate cancer. Thus, future studies in-cooperating randomised clinical trials are essential for clinicians to provide prevention of prostate cancer for diabetic patients. In the long term, this can reduce healthcare resource expenditure and refine clinical guidelines that govern treatment for prostate cancer and diabetes. This study has explored the relationship of data obtained from routine clinical practice in Hong Kong. This study suggests that SGLT2I may demonstrate a more significant overall protective effect against prostate cancer compared to DPP4I. Previously, metformin was suggested to be associated with reduced mortality amongst prostate cancer patients independent of diabetic control [42]. As such, SGLT2I may also play a role in altering the cancer outcomes and prognosis amongst prostate cancer patients.

Limitations

Several limitations should be noted in this study. Due to the observational nature of this study variables which predict prostate cancer, such as BMI, alcohol use, smoking, socioeconomic status, family history of prostate cancer, and screening PSA level, were not available from CDARS. This was attempted to be addressed by including laboratory results and comorbidities to infer the potential risk factors. To further compensate for this, we have matched our drug cohorts over an array of diseases and medications, adjusted the regression, and conducted a range of sensitivity analyses to minimise bias. Besides, there is potential under-coding, coding errors, and missing data leading to information bias due to the nature of the study. Moreover, the patient's level of compliance and drug exposure duration could not be standardised. Lastly, the retrospective design of our study necessitates the presentation of

344

345

346

347

348

349

350

351

352

353

354 355

356

357

358

359

360

361

362

363

364

365

366

367

associations but not causal links between SGLT2I versus DPP4I use and the risk of new-onset prostate cancer. Therefore, further research is warranted to explore the beneficial effects of SGLT2I. Conclusion In this population-based cohort study, SGLT2I users were associated with lower risks of new-onset prostate cancer than DPP4I users amongst T2DM patients. These results may have potential clinical implications in preventing cancer among T2DM patients. Further randomised controlled trials and mechanistic studies into prostate cancer with SGLT2I are needed. **Funding source** The authors received no funding for the research, authorship, and/or publication of this article. **Conflicts of Interest** None. **Ethical approval statement** This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKWC IRB) (UW-20-250), and New Territories East Cluster-Chinese University of Hong Kong (NTEC-UCHK) Clinical Research Ethnics Committee (2018.309, 2018.643) and complied with the Declaration of Helsinki.

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

Availability of data and materials Data are not available, as the data custodians (the Hospital Authority and the Department of Health of Hong Kong SAR) have not given permission for sharing due to patient confidentiality concerns. Local academic institutions, government departments, nongovernmental organizations may apply for the access to data through the Hospital Authority's data sharing portal (https://www3.ha.org.hk/data). Acknowledgements None. **Guarantor Statement** All authors approved the final version of the manuscript. GT is the guaranter of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. **Author contributions** Data analysis: OHIC, LL, JZ Data review: OHIC, JSKC, RNCC, SL, GT, JZ Data acquisition: OHIC, HHHP, SL Data interpretation: OHIC, CTC, JSKC, BMYC, GT, JZ Critical revision of manuscription: JSKC, RNCC, ALYH, ECD, KN, BMYC, GT, JZ Supervision: BMYC, GT, JZ

- 391 Manuscript writing: OHIC, CTC, JSKC, ALYH, KKW
- 392 Manuscript revision: OHIC, JSKC, ALYH, ECD, KN, BMYC, GT, JZ

Reference

393394

- 396 [1] Maruthur NM. The Growing Prevalence of Type 2 Diabetes: Increased Incidence or
- 397 Improved Survival? Current Diabetes Reports. 2013;13:786-94.
- 398 [2] Leslie SW, Soon-Sutton TL, R IA, Sajjad H, Siref LE. Prostate Cancer. StatPearls.
- 399 Treasure Island (FL): StatPearls Publishing
- 400 Copyright © 2023, StatPearls Publishing LLC.; 2023.
- 401 [3] Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate Cancer Incidence and Mortality:
- 402 Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front Public Health.
- 403 2022;10:811044.
- 404 [4] Li Q, Kuriyama S, Kakizaki M, Yan H, Sone T, Nagai M, et al. History of diabetes
- 405 mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes & Control.
- 406 2010;21:1025-32.
- 407 [5] Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate
- 408 cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16:151-
- 409 8, s1.
- 410 [6] Chung CT, Lakhani I, Chou OHI, Lee TTL, Dee C, Ng K, et al. Sodium-glucose
- cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer
- in Type 2 diabetes mellitus: A population-based study. Cancer Med. 2023.
- 413 [7] Olokpa E, Mandape SN, Pratap S, Stewart LMV. Metformin regulates multiple signaling
- pathways within castration-resistant human prostate cancer cells. BMC Cancer.
- 415 2022;22:1025.
- 416 [8] Clements A, Gao B, Yeap S, Wong M, Ali S, Gurney H. Metformin in prostate cancer:
- 417 two for the price of one. Annals of oncology. 2011;22:2556-60.
- 418 [9] Lee YHA, Zhou J, Hui JMH, Liu X, Lee TTL, Hui K, et al. Risk of New-Onset Prostate
- 419 Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity
- 420 Score-Matched Study. J Natl Compr Canc Netw. 2022;20:674-82.e15.
- 421 [10] Chen CB, Eskin M, Eurich DT, Majumdar SR, Johnson JA. Metformin, Asian ethnicity
- and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis. Bmc
- 423 Cancer. 2018;18:1-7.
- 424 [11] Crunkhorn S. Repurposing SGLT2 inhibitors. Nature Reviews Drug Discovery.
- 425 2019;18:18-.
- 426 [12] Rokszin G, Kiss Z, Sütő G, Kempler P, Jermendy G, Fábián I, et al. Sodium-Glucose
- 427 Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and
- 428 Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of
- the Post-Hoc Analysis of a Nationwide Study. Frontiers in Oncology. 2021;11:725465.
- 430 [13] Lau IT. A Clinical Practice Guideline to Guide a System Approach to Diabetes Care in
- 431 Hong Kong. Diabetes Metab J. 2017;41:81-8.
- 432 [14] Au PCM, Tan KCB, Lam DCL, Cheung BMY, Wong ICK, Kwok WC, et al.
- 433 Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor
- 434 Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among
- Patients With Type 2 Diabetes in Hong Kong. JAMA Netw Open. 2023;6:e2251177.
- 436 [15] Zhou J, Liu X, Chou OH, Li L, Lee S, Wong WT, et al. Lower risk of gout in sodium
- glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors
- 438 in type-2 diabetes. Rheumatology (Oxford). 2023;62:1501-10.

- 439 [16] Chou OHI, Zhou J, V Mui J, Satti DI, Chung CT, Tai Loy Lee T, et al. Lower risks of
- new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2
- 441 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors: A propensity
- score-matched study with competing risk analysis. Diabetes Epidemiology and Management.
- 443 2023;9:100115.
- 444 [17] Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: A
- 445 Critical Review of Clinimetric Properties. Psychother Psychosom. 2022;91:8-35.
- 446 [18] Soliman AR, Fathy A, Khashab S, Shaheen N. Comparison of abbreviated modification
- of diet in renal disease formula (aMDRD) and the Cockroft-Gault adjusted for body surface
- 448 (aCG) equations in stable renal transplant patients and living kidney donors. Ren Fail.
- 449 2013;35:94-7.
- 450 [19] Lau KTK, Wong CKH, Au ICH, Lau WCY, Man KKC, Chui CSL, et al. Switching to
- Versus Addition of Incretin-Based Drugs Among Patients With Type 2 Diabetes Taking
- 452 Sodium-Glucose Cotransporter-2 Inhibitors. Journal of the American Heart Association.
- 453 2022;11:e023489.
- 454 [20] Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of
- 455 Confounding in Observational Studies. Multivariate Behav Res. 2011;46:399-424.
- 456 [21] Austin PC, Stuart EA. Moving towards best practice when using inverse probability of
- 457 treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in
- observational studies. Stat Med. 2015;34:3661-79.
- 459 [22] Avagyan V, Vansteelandt S. Stable inverse probability weighting estimation for
- longitudinal studies. Scandinavian Journal of Statistics. 2021;48:1046-67.
- 461 [23] Zhang L, Yang BX, Zhang HT, Wang JG, Wang HL, Zhao XJ. Prostate cancer: an
- emerging threat to the health of aging men in Asia. Asian J Androl. 2011;13:574-8.
- 463 [24] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
- 464 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
- 465 Cancers in 185 Countries, CA: A Cancer Journal for Clinicians, 2021;71:209-49.
- 466 [25] Gu Y, Hou X, Zheng Y, Wang C, Zhang L, Li J, et al. Incidence and Mortality Risks of
- 467 Cancer in Patients with Type 2 Diabetes: A Retrospective Study in Shanghai, China. Int J
- 468 Environ Res Public Health. 2016;13.
- 469 [26] Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality
- after incident cancer in people with and without type 2 diabetes: impact of metformin on
- 471 survival. Diabetes care. 2012:35:299-304.
- 472 [27] Lee J, Giovannucci E, Jeon JY. Diabetes and mortality in patients with prostate cancer: a
- 473 meta-analysis. Springerplus. 2016;5:1548.
- 474 [28] Feng X, Song M, Preston MA, Ma W, Hu Y, Pernar CH, et al. The association of
- diabetes with risk of prostate cancer defined by clinical and molecular features. British
- 476 Journal of Cancer. 2020;123:657-65.
- 477 [29] Pelletier R, Ng K, Alkabbani W, Labib Y, Mourad N, Gamble JM. The association of
- sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative
- 479 systematic reviews. Endocrinol Diabetes Metab. 2020;3:e00145.
- 480 [30] Cui H, Wang Y, Yang S, He G, Jiang Z, Gang X, et al. Antidiabetic medications and the
- risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-
- analysis. Pharmacological Research. 2022:106094.
- 483 [31] Lu Z, Qi L, Bo XJ, Liu GD, Wang JM, Li G. Expression of CD26 and CXCR4 in
- prostate carcinoma and its relationship with clinical parameters. J Res Med Sci. 2013;18:647-
- 485 52.
- 486 [32] Bekele K, Smith T, Stewart L. The SGLT2 Inhibitor Canagliflozin Reduces Androgen
- 487 Receptor Expression and Nuclear Localization of Beta-Catenin in Human Prostate Cancer
- 488 Cells. 2022.

- 489 [33] Benedetti R, Benincasa G, Glass K, Chianese U, Vietri MT, Congi R, et al. Effects of
- 490 novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of
- 491 randomized clinical trials. Pharmacological Research. 2022;175:106039.
- 492 [34] Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T. Effects of
- 493 canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells:
- 494 Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
- 495 PLoS One. 2020;15:e0232283.
- 496 [35] Zhou J, Zhu J, Yu SJ, Ma HL, Chen J, Ding XF, et al. Sodium-glucose co-transporter-2
- 497 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest
- through AMPK/mTOR pathway. Biomed Pharmacother. 2020;132:110821.
- 499 [36] Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, et al. Functional
- 500 expression of sodium-glucose transporters in cancer. Proceedings of the National Academy of
- 501 Sciences. 2015;112:E4111-E9.
- 502 [37] Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE, et al. The
- diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting
- mitochondrial complex-I supported respiration. Molecular metabolism. 2016;5:1048-56.
- 505 [38] Wilcox CS. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose
- Linked Transporter 2) Inhibitors. Hypertension. 2020;75:894-901.
- 507 [39] Lu S, Yin H, Yu OHY, Azoulay L. Incretin-Based Drugs and the Incidence of Prostate
- Cancer Among Patients With Type 2 Diabetes. Epidemiology. 2022;33:563-71.
- 509 [40] Tseng CH. Sitagliptin may reduce prostate cancer risk in male patients with type 2
- 510 diabetes. Oncotarget. 2017;8:19057-64.

- 511 [41] Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB. Neoplasms Reported With
- Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER
- Randomized Trial. Diabetes Care. 2018;41:1663-71.
- 514 [42] Lee YHA, Hui JMH, Chan JSK, Liu K, Dee EC, Ng K, et al. Metformin use and
- 515 mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A
- population-based study. Prostate. 2023;83:119-27.

Table 1. Baseline and clinical characteristics of patients with SGLT2I v.s. DPP4I use before and after propensity score matching (1:1).

* for SMD \geq 0.1; SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor; MDRD: modification of diet in renal disease; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin II receptor blockers.

	Before matching				After matching			
Characteristics	All (N=42129) Mean(SD);N or Count(%)	SGLT2I (N=17120) Mean(SD);N or Count(%)	DPP4I (N=25009) Mean(SD);N or Count(%)	SMD	All (N=34240) Mean(SD);N or Count(%)	SGLT2I (N=17120) Mean(SD);N or Count(%)	DPP4I (N=17120) Mean(SD);N or Count(%)	SMD
Demographics								
Baseline age, years	61.0(12.2);n=42129	57.3(10.9);n=17120	63.5(12.4);n=25009	0.53*	57.7(10.7);n=34240	57.3(10.9);n=17120	58.2(10.5);n=17120	0.08
Past comorbidities								
Charlson standard comorbidity index	1.9(1.5);n=42129	1.5(1.2);n=17120	2.2(1.6);n=25009	0.47*	1.5(1.2);n=34240	1.5(1.2);n=17120	1.6(1.2);n=17120	0.05
Duration from earliest diabetes mellitus diagnosis date to baseline date, years	6.5(4.9);n=42129	6.8(4.9);n=17120	6.3(4.9);n=25009	0.1	6.7(5.0);n=34240	6.8(4.9);n=17120	6.5(5.1);n=17120	0.07
Number of prior hospitalizations	1.2(0.8);n=42129	1.3(1.1);n=17120	1.2(0.6);n=25009	0.17	1.3(1.0);n=34240	1.3(1.1);n=17120	1.2(0.9);n=17120	0.08
Hyperlipidaemia	30441(72.25%)	12812(74.83%)	17629(70.49%)	0.1	25853(75.50%)	12812(74.83%)	13041(76.17%)	0.03
Hypertension	25490(60.50%)	15280(89.25%)	10210(40.82%)	1.18*	24440(71.37%)	12280(71.72%)	12160(71.02%)	0.02
Urinary tract infection	1493(3.54%)	415(2.42%)	1078(4.31%)	0.1	807(2.35%)	415(2.42%)	392(2.28%)	0.01
Cancer	731(1.73%)	209(1.22%)	522(2.08%)	0.07	415(1.21%)	209(1.22%)	206(1.20%)	<0.01
Autoimmune disease	330(0.78%)	137(0.80%)	193(0.77%)	<0.01	272(0.79%)	137(0.80%)	135(0.78%)	<0.01
Heart failure	1328(3.15%)	495(2.89%)	833(3.33%)	0.03	979(2.85%)	495(2.89%)	484(2.82%)	<0.01
Ischemic heart disease	5200(12.34%)	2677(15.63%)	2523(10.08%)	0.17	5013(14.64%)	2577(15.05%)	2436(14.22%)	0.02
Acute myocardial infarction	1541(3.65%)	771(4.50%)	770(3.07%)	0.07	1513(4.41%)	771(4.50%)	742(4.33%)	0.01

Selicion									
Stroke/transient schemic attack 1259(2.98%) 423(2.47%) 836(3.34%) 0.05 836(2.44%) 423(2.47%) 413(2.41%) < 0.01	Peripheral vascular disease	341(0.80%)	98(0.57%)	243(0.97%)	0.05	196(0.57%)	98(0.57%)	98(0.57%)	<0.01
Schemic attack 1259(2.98%) 423(2.4%) 836(3.3%) 0.05 836(2.4%) 423(2.4%) 413(2.4%) < 0.01 Diabetic retinopathy 2723(6.46%) 1019(5.95%) 1704(6.81%) 0.04 1926(5.62%) 1019(5.95%) 907(5.29%) 0.03 Diabetic neuropathy 872(2.06%) 311(1.81%) 561(2.24%) 0.03 322(0.67%) 311(1.81%) 290(1.69%) 0.01 Renal diseases 3269(7.75%) 899(5.25%) 2370(9.47%) 0.16 1704(4.97%) 899(5.25%) 805(4.70%) 0.03 Liver diseases 1741(4.13%) 807(4.71%) 344(1.37%) 0.05 1520(4.43%) 807(4.71%) 121(0.70%) 0.03 Chronic obstructive pulmonary disease 466(1.10%) 122(0.71%) 344(1.37%) 0.05 122(0.43%) 807(4.71%) 121(0.70%) 0.03 Metformin 37650(89.36%) 15922(93.00%) 21728(86.88%) 0.20* 127(32.8);n=34240 12.7(32.8);n=17120 12.8(32.7);n=17120 0.01* Metformin 37650(89.36%) 15922(93.00%) 21728(86.88%) 0.20* 12040(49.94%) 8455(49.38%) 12585(50.32%) 0.02 16773(48.98%) 8455(49.38%) 13647(79.71%) 0.17* Insulin 21040(49.94%) 8455(49.38%) 12585(50.32%) 0.04 1235(3.60%) 640(3.73%) 595(3.47%) 0.01* Thiazolidinedion 8506(20.19%) 1496(6.62%) 1596(6.62%) 1596(6.62%) 1596(6.62%) 1596(6.32%) 1596(6.62%) 1596(6.62%) 1596(6.62%) 1596(6.62%) 1596(6.62%) 0.01* Glucagon-like peptide-1 receptor agonists 2668(6.32%) 1596(6.69%) 1596(6.69%) 1744(4.69.9%) 0.03* 2252(51.66%) 1216(74.27%) 12509(73.06%) 0.03* 2252(51.66%) 1216(74.27%) 12509(73.06%) 0.03* 2252(51.66%) 1216(6.68%) 10563(61.69%) 0.03* 2004(6.69.5%) 1120(61.68%) 10563(61.69%) 0.03* 2004(6.69.5%) 1120(61.68%) 10563(61.69%) 0.03* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 20	Atrial fibrillation	993(2.35%)	370(2.16%)	623(2.49%)	0.02	724(2.11%)	370(2.16%)	354(2.06%)	0.01
Diabetic nephropathy	Stroke/transient ischemic attack	1259(2.98%)	423(2.47%)	836(3.34%)	0.05	836(2.44%)	423(2.47%)	413(2.41%)	<0.01
Pacific Paci	Diabetic retinopathy	2723(6.46%)	1019(5.95%)	1704(6.81%)	0.04	1926(5.62%)	1019(5.95%)	907(5.29%)	0.03
Renal diseases 3269(7.75%) 899(5.25%) 2370(9.47%) 0.16 1704(4.97%) 899(5.25%) 805(4.70%) 0.03 1004 1005 1005 1005 1005 1005 1005 1005	Diabetic nephropathy	528(1.25%)	116(0.67%)	412(1.64%)	0.09	232(0.67%)	116(0.67%)	116(0.67%)	<0.01
Liver diseases 1741(4.13%) 807(4.71%) 934(3.73%) 0.05 1520(4.43%) 807(4.71%) 713(4.16%) 0.03 Chronic obstructive pulmonary diseases	Diabetic neuropathy	872(2.06%)	311(1.81%)	561(2.24%)	0.03	601(1.75%)	311(1.81%)	290(1.69%)	0.01
Chronic obstructive pulmonary disease	Renal diseases	3269(7.75%)	899(5.25%)	2370(9.47%)	0.16	1704(4.97%)	899(5.25%)	805(4.70%)	0.03
Pulmonary disease 466(1.10%) 122(0.71%) 344(1.37%) 0.07 243(0.70%) 122(0.71%) 121(0.70%) <0.01	Liver diseases	1741(4.13%)	807(4.71%)	934(3.73%)	0.05	1520(4.43%)	807(4.71%)	713(4.16%)	0.03
Number of anti- diabetic drugs Netformin 37650(89.36%) 15922(93.00%) 21728(86.88%) 20063(80.22%) 0.20 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(32.32%) 3256(32.33%) 32664(3.73%) 32664(3.73%) 32664(3.73%) 32664(3.73%) 32664(3.73%) 3267(55.84%) 3267(55.84%) 3267(55.84%) 3267(32.8);n=34240 32.7(32.8);n=34240 32.7(32.8);n=34240 32.7(32.8);n=17120 32.8(32.7);n=17120 32.8(32.8);n=34240 32.7(32.8);n=34240 3	Chronic obstructive pulmonary disease	466(1.10%)	122(0.71%)	344(1.37%)	0.07	243(0.70%)	122(0.71%)	121(0.70%)	<0.01
diabetic drugs 9.5(26.7);n=42129 12.7(32.8);n=17120 7.3(21.3);n=25009 0.2 12.7(32.8);n=34240 12.7(32.8);n=17120 12.8(32.7);n=17120 <0.01	Medications								
Sulphonylurea 32456(77.03%) 12393(72.38%) 20063(80.22%) 0.19 26040(76.05%) 12393(72.38%) 13647(79.71%) 0.17* Insulin 21040(49.94%) 8455(49.38%) 12585(50.32%) 0.02 16773(48.98%) 8455(49.38%) 8318(48.58%) 0.02 Acarbose 1402(3.32%) 640(3.73%) 762(3.04%) 0.04 1235(3.60%) 640(3.73%) 595(3.47%) 0.01 Thiazolidinedione 8506(20.19%) 4448(25.98%) 4058(16.22%) 0.24* 8131(23.74%) 4448(25.98%) 3683(21.51%) 0.11* Glucagon-like peptide-1 receptor 2666(6.32%) 1159(6.76%) 1507(6.02%) 0.03 2250(6.57%) 1159(6.76%) 1091(6.37%) 0.02 agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01	Number of anti- diabetic drugs	9.5(26.7);n=42129	12.7(32.8);n=17120	7.3(21.3);n=25009	0.2	12.7(32.8);n=34240	12.7(32.8);n=17120	12.8(32.7);n=17120	<0.01
Insulin 21040(49.94%) 8455(49.38%) 12585(50.32%) 0.02 16773(48.98%) 8455(49.38%) 8318(48.58%) 0.02 Acarbose 1402(3.32%) 640(3.73%) 762(3.04%) 0.04 1235(3.60%) 640(3.73%) 595(3.47%) 0.01 Thiazolidinedione 8506(20.19%) 4448(25.98%) 4058(16.22%) 0.24* 8131(23.74%) 4448(25.98%) 3683(21.51%) 0.11* Glucagon-like peptide-1 receptor 2666(6.32%) 1159(6.76%) 1507(6.02%) 0.03 2250(6.57%) 1159(6.76%) 1091(6.37%) 0.02 agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12	Metformin	37650(89.36%)	15922(93.00%)	21728(86.88%)	0.20*	31909(93.19%)	15922(93.00%)	15987(93.38%)	0.02
Acarbose 1402(3.32%) 640(3.73%) 762(3.04%) 0.04 1235(3.60%) 640(3.73%) 595(3.47%) 0.01 Thiazolidinedione 8506(20.19%) 4448(25.98%) 4058(16.22%) 0.24* 8131(23.74%) 4448(25.98%) 3683(21.51%) 0.11* Glucagon-like peptide-1 receptor 2666(6.32%) 1159(6.76%) 1507(6.02%) 0.03 2250(6.57%) 1159(6.76%) 1091(6.37%) 0.02 agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	Sulphonylurea	32456(77.03%)	12393(72.38%)	20063(80.22%)	0.19	26040(76.05%)	12393(72.38%)	13647(79.71%)	0.17*
Thiazolidinedione 8506(20.19%) 4448(25.98%) 4058(16.22%) 0.24* 8131(23.74%) 4448(25.98%) 3683(21.51%) 0.11* Glucagon-like peptide-1 receptor 2666(6.32%) 1159(6.76%) 1507(6.02%) 0.03 2250(6.57%) 1159(6.76%) 1091(6.37%) 0.02 agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	Insulin	21040(49.94%)	8455(49.38%)	12585(50.32%)	0.02	16773(48.98%)	8455(49.38%)	8318(48.58%)	0.02
Glucagon-like peptide-1 receptor 2666(6.32%) 1159(6.76%) 1507(6.02%) 0.03 agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	Acarbose	1402(3.32%)	640(3.73%)	762(3.04%)	0.04	1235(3.60%)	640(3.73%)	595(3.47%)	0.01
peptide-1 receptor 2666(6.32%) 1159(6.76%) 1507(6.02%) 0.03 2250(6.57%) 1159(6.76%) 1091(6.37%) 0.02 agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	Thiazolidinedione	8506(20.19%)	4448(25.98%)	4058(16.22%)	0.24*	8131(23.74%)	4448(25.98%)	3683(21.51%)	0.11*
agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	Glucagon-like								
ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	peptide-1 receptor agonists	2666(6.32%)	1159(6.76%)	1507(6.02%)	0.03	2250(6.57%)	1159(6.76%)	1091(6.37%)	0.02
Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	Statins and fibrates	26683(63.33%)	12716(74.27%)	13967(55.84%)	0.39*	25225(73.67%)	12716(74.27%)	12509(73.06%)	0.03
	ACEI/ARB	22307(52.94%)	10563(61.69%)	11744(46.95%)	0.30*	21120(61.68%)	10563(61.69%)	10557(61.66%)	<0.01
Beta-blockers 11878(28.19%) 5048(29.48%) 6830(27.31%) 0.05 10565(30.85%) 5048(29.48%) 5517(32.22%) 0.06	Diuretics	12276(29.13%)	5536(32.33%)	6740(26.95%)	0.12	11411(33.32%)	5536(32.33%)	5875(34.31%)	0.04
	Beta-blockers	11878(28.19%)	5048(29.48%)	6830(27.31%)	0.05	10565(30.85%)	5048(29.48%)	5517(32.22%)	0.06

Calcium channel blockers (dihydropyridine)	21531(51.10%)	9919(57.93%)	11612(46.43%)	0.23*	19921(58.18%)	9919(57.93%)	10002(58.42%)	0.01
Calcium channel								
blocker (non-	11656(27.66%)	5014(29.28%)	6642(26.55%)	0.06	9795(28.60%)	5014(29.28%)	4781(27.92%)	0.03
dihydropyridine)	,	(,	(, , , , , , , , , , , , , , , , , , , ,	(- (
Systemic steroids	269(0.63%)	126(0.73%)	143(0.57%)	0.02	252(0.73%)	126(0.73%)	126(0.73%)	<0.01
Antiplatelets	13825(32.81%)	6401(37.38%)	7424(29.68%)	0.16	12869(37.58%)	6401(37.38%)	6468(37.78%)	0.01
Alpha-blockers	7488(17.77%)	2624(15.32%)	4864(19.44%)	0.11	5033(14.69%)	2624(15.32%)	2409(14.07%)	0.04
Aspirin	12408(29.45%)	5963(34.83%)	6445(25.77%)	0.2	11902(34.76%)	5963(34.83%)	5939(34.69%)	<0.01
Calculated biomarker	` '	,	, ,		, , ,	,	, ,	
Abbreviated MDRD, mL/min/1.73m^2	80.8(26.9);n=34221	88.6(22.6);n=14077	75.4(28.3);n=20144	0.51*	87.5(23.2);n=28366	88.6(22.6);n=14077	86.4(23.7);n=14289	0.09
Renal function tests								
Creatinine, umol/L	103.7(79.5);n=34221	87.9(29.0);n=14077	114.8(99.2);n=20144	0.37*	89.7(37.2);n=28366	87.9(29.0);n=14077	91.4(43.8);n=14289	0.09
Lipid tests								
Triglyceride, mmol/L	1.7(1.8);n=32353	1.9(2.0);n=13493	1.7(1.6);n=18860	0.1	1.9(2.0);n=27134	1.85(1.96);n=13493	1.87(2.08);n=13641	0.01
Low-density lipoprotein, mmol/L	2.4(0.8);n=31726	2.3(0.8);n=13219	2.4(0.8);n=18507	0.04	2.4(0.8);n=26546	2.3(0.8);n=13219	2.4(0.8);n=13327	0.05
High-density lipoprotein, mmol/L	1.1(0.3);n=32298	1.09(0.28);n=13468	1.14(0.31);n=18830	0.14	1.1(0.3);n=27093	1.09(0.28);n=13468	1.1(0.29);n=13625	0.04
Total cholesterol, mmol/L	4.2(1.0);n=32387	4.22(1.01);n=13510	4.23(0.99);n=18877	0.01	4.3(1.0);n=27166	4.2(1.0);n=13510	4.3(1.0);n=13656	0.06
Glucose tests								
Haemoglobin A1C, %	8.1(1.6);n=33538	8.3(1.6);n=13824	8.0(1.6);n=19714	0.18	8.3(1.6);n=27789	8.25(1.61);n=13824	8.26(1.58);n=13965	0.01
Fasting glucose, mmol/L	9.0(3.9);n=30477	9.2(3.6);n=12691	8.8(4.2);n=17786	0.08	9.2(3.8);n=25612	9.2(3.6);n=12691	9.3(4.1);n=12921	0.04

Table 2. Incidence rate (IR) per 1000 person-year of new onset prostate cancer, cancerrelated mortality, and all-cause mortality in the cohort before and after 1:1 propensity score matching.

SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor; MDRD: modification of diet in renal disease

Adjusted for significant demographics, past comorbidities, duration of diabetes mellitus, number of prior hospitalizations, number of anti-diabetic drugs, non-SGLT2I/DPP4I medications, abbreviated MDRD, HbA1c, fasting glucose.

Prostate	Number of	Number	Total	Follow-up	Incidence	Adjusted	P-value
cancer	patients	of events	person-	duration, years	[95% CI]	hazard ratio	
			year	[95% CI]		[95% CI]	
DPP4I	17120	102	92074.6	5.6 [5.31-5.83]	1.11[0.90-	1 [reference]	NA
					1.34]		
SGLT2I	17120	60	94794.8	5.62 [5.35-5.83]	0.63[0.48-	0.45[0.30-0.70]	0.0003
					0.81]		
Cancer-	Number of	Number	Total	Follow-up	Incidence	Adjusted	P value
related	patients	of events	person-	duration, years	[95% CI]	hazard ratio	
mortality			year	[95% CI]		[95% CI]	
DPP4I	17120	260	92299.7	5.6 [5.31-5.83]	2.81[2.48-	1 [reference]	NA
					3.18]		
SGLT2I	17120	99	94892.2	5.62 [5.33-5.82]	1.04[0.85-	0.57[0.40-0.76]	<0.0001
					1.27]		
All-cause	Number of	Number	Total	Follow-up	Incidence	Adjusted	P value
mortality	patients	of events	person-	duration, years	[95% CI]	hazard ratio	
			year	[95% CI]		[95% CI]	
DPP4I	17120	1652	92299.7	5.6 [5.31-5.83]	17.9[17.0-	1 [reference]	NA
					18.8]		
SGLT2I	17120	541	94892.2	5.62 [5.35-5.82]	5.70[5.23-	0.68[0.46-0.78]	< 0.0001
		541			6.20]		







Figure 1. Procedures of data processing for the study cohort

SGLT2I: Sodium-glucose cotransporter-2 inhibitors; DPP4I: Dipeptidyl peptidase-4 inhibitors. MDRD: modification of diet in renal disease.










Figure 2. Cumulative incidence curves for new onset prostate cancer, cancer-related mortality, and all-cause mortality stratified by drug exposure effects of SGLT2I and DPP4I after propensity score matching (1:1).

SGLT2I: Sodium-glucose cotransporter-2 inhibitors; DPP4I: Dipeptidyl peptidase-4 inhibitors




Figure 3. Subgroup analyses for SGLT2I v.s. DPP4I exposure predict prostate cancer in the matched cohort.

SGLT2I: Sodium-glucose cotransporter-2 inhibitors; DPP4I: Dipeptidyl peptidase-4 inhibitors.Q1: Quartile 1Q2: Quartile 2; Q3: Quartile 3; Q4: Quartile 4; CI: Confidence interval

Table 1. Baseline and clinical characteristics of patients with SGLT2I v.s. DPP4I use before and after propensity score matching (1:1).

* for SMD \geq 0.1; SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor; MDRD: modification of diet in renal disease; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin II receptor blockers.

	Before matching				After matching			
Characteristics	All (N=42129) Mean(SD);N or Count(%)	SGLT2I (N=17120) Mean(SD);N or Count(%)	DPP4I (N=25009) Mean(SD);N or Count(%)	SMD	All (N=34240) Mean(SD);N or Count(%)	SGLT2I (N=17120) Mean(SD);N or Count(%)	DPP4I (N=17120) Mean(SD);N or Count(%)	SMD
Demographics								
Baseline age, years	61.0(12.2);n=42129	57.3(10.9);n=17120	63.5(12.4);n=25009	0.53*	57.7(10.7);n=34240	57.3(10.9);n=17120	58.2(10.5);n=17120	0.08
Past comorbidities								
Charlson standard comorbidity index	1.9(1.5);n=42129	1.5(1.2);n=17120	2.2(1.6);n=25009	0.47*	1.5(1.2);n=34240	1.5(1.2);n=17120	1.6(1.2);n=17120	0.05
Duration from earliest diabetes mellitus diagnosis date to baseline date, years	6.5(4.9);n=42129	6.8(4.9);n=17120	6.3(4.9);n=25009	0.1	6.7(5.0);n=34240	6.8(4.9);n=17120	6.5(5.1);n=17120	0.07
Number of prior hospitalizations	1.2(0.8);n=42129	1.3(1.1);n=17120	1.2(0.6);n=25009	0.17	1.3(1.0);n=34240	1.3(1.1);n=17120	1.2(0.9);n=17120	0.08
Hyperlipidaemia	30441(72.25%)	12812(74.83%)	17629(70.49%)	0.1	25853(75.50%)	12812(74.83%)	13041(76.17%)	0.03
Hypertension	25490(60.50%)	15280(89.25%)	10210(40.82%)	1.18*	24440(71.37%)	12280(71.72%)	12160(71.02%)	0.02
Urinary tract infection	1493(3.54%)	415(2.42%)	1078(4.31%)	0.1	807(2.35%)	415(2.42%)	392(2.28%)	0.01
Cancer	731(1.73%)	209(1.22%)	522(2.08%)	0.07	415(1.21%)	209(1.22%)	206(1.20%)	<0.01
Autoimmune disease	330(0.78%)	137(0.80%)	193(0.77%)	<0.01	272(0.79%)	137(0.80%)	135(0.78%)	<0.01
Heart failure	1328(3.15%)	495(2.89%)	833(3.33%)	0.03	979(2.85%)	495(2.89%)	484(2.82%)	<0.01
Ischemic heart disease	5200(12.34%)	2677(15.63%)	2523(10.08%)	0.17	5013(14.64%)	2577(15.05%)	2436(14.22%)	0.02
Acute myocardial infarction	1541(3.65%)	771(4.50%)	770(3.07%)	0.07	1513(4.41%)	771(4.50%)	742(4.33%)	0.01

Selicion									
Stroke/transient schemic attack 1259(2.98%) 423(2.47%) 836(3.34%) 0.05 836(2.44%) 423(2.47%) 413(2.41%) < 0.01	Peripheral vascular disease	341(0.80%)	98(0.57%)	243(0.97%)	0.05	196(0.57%)	98(0.57%)	98(0.57%)	<0.01
Schemic attack 1259(2.98%) 423(2.4%) 836(3.3%) 0.05 836(2.4%) 423(2.4%) 413(2.4%) < 0.01 Diabetic retinopathy 2723(6.46%) 1019(5.95%) 1704(6.81%) 0.04 1926(5.62%) 1019(5.95%) 907(5.29%) 0.03 Diabetic neuropathy 872(2.06%) 311(1.81%) 561(2.24%) 0.03 322(0.67%) 311(1.81%) 290(1.69%) 0.01 Renal diseases 3269(7.75%) 899(5.25%) 2370(9.47%) 0.16 1704(4.97%) 899(5.25%) 805(4.70%) 0.03 Liver diseases 1741(4.13%) 807(4.71%) 344(1.37%) 0.05 1520(4.43%) 807(4.71%) 121(0.70%) 0.03 Chronic obstructive pulmonary disease 466(1.10%) 122(0.71%) 344(1.37%) 0.05 122(0.43%) 807(4.71%) 121(0.70%) 0.03 Metformin 37650(89.36%) 15922(93.00%) 21728(86.88%) 0.20* 127(32.8);n=34240 12.7(32.8);n=17120 12.8(32.7);n=17120 0.01* Metformin 37650(89.36%) 15922(93.00%) 21728(86.88%) 0.20* 12040(49.94%) 8455(49.38%) 12585(50.32%) 0.02 16773(48.98%) 8455(49.38%) 13647(79.71%) 0.17* Insulin 21040(49.94%) 8455(49.38%) 12585(50.32%) 0.04 1235(3.60%) 640(3.73%) 595(3.47%) 0.01* Thiazolidinedion 8506(20.19%) 1496(6.62%) 1596(6.62%) 1596(6.62%) 1596(6.62%) 1596(6.32%) 1596(6.62%) 1596(6.62%) 1596(6.62%) 1596(6.62%) 1596(6.62%) 0.01* Glucagon-like peptide-1 receptor agonists 2668(6.32%) 1596(6.69%) 1596(6.69%) 1744(4.69.9%) 0.03* 2252(51.66%) 1216(74.27%) 12509(73.06%) 0.03* 2252(51.66%) 1216(74.27%) 12509(73.06%) 0.03* 2252(51.66%) 1216(6.68%) 10563(61.69%) 0.03* 2004(6.69.5%) 1120(61.68%) 10563(61.69%) 0.03* 2004(6.69.5%) 1120(61.68%) 10563(61.69%) 0.03* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 2004(6.69.5%) 0.04* 20	Atrial fibrillation	993(2.35%)	370(2.16%)	623(2.49%)	0.02	724(2.11%)	370(2.16%)	354(2.06%)	0.01
Diabetic nephropathy	Stroke/transient ischemic attack	1259(2.98%)	423(2.47%)	836(3.34%)	0.05	836(2.44%)	423(2.47%)	413(2.41%)	<0.01
Pacific Paci	Diabetic retinopathy	2723(6.46%)	1019(5.95%)	1704(6.81%)	0.04	1926(5.62%)	1019(5.95%)	907(5.29%)	0.03
Renal diseases 3269(7.75%) 899(5.25%) 2370(9.47%) 0.16 1704(4.97%) 899(5.25%) 805(4.70%) 0.03 1004 1005 1005 1005 1005 1005 1005 1005	Diabetic nephropathy	528(1.25%)	116(0.67%)	412(1.64%)	0.09	232(0.67%)	116(0.67%)	116(0.67%)	<0.01
Liver diseases 1741(4.13%) 807(4.71%) 934(3.73%) 0.05 1520(4.43%) 807(4.71%) 713(4.16%) 0.03 Chronic obstructive pulmonary diseases	Diabetic neuropathy	872(2.06%)	311(1.81%)	561(2.24%)	0.03	601(1.75%)	311(1.81%)	290(1.69%)	0.01
Chronic obstructive pulmonary disease	Renal diseases	3269(7.75%)	899(5.25%)	2370(9.47%)	0.16	1704(4.97%)	899(5.25%)	805(4.70%)	0.03
Pulmonary disease 466(1.10%) 122(0.71%) 344(1.37%) 0.07 243(0.70%) 122(0.71%) 121(0.70%) <0.01	Liver diseases	1741(4.13%)	807(4.71%)	934(3.73%)	0.05	1520(4.43%)	807(4.71%)	713(4.16%)	0.03
Number of anti- diabetic drugs Netformin 37650(89.36%) 15922(93.00%) 21728(86.88%) 20063(80.22%) 0.20 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(77.03%) 32456(32.32%) 3256(32.33%) 32664(3.73%) 32664(3.73%) 32664(3.73%) 32664(3.73%) 32664(3.73%) 3267(55.84%) 3267(55.84%) 3267(55.84%) 3267(32.8);n=34240 32.7(32.8);n=34240 32.7(32.8);n=34240 32.7(32.8);n=17120 32.8(32.7);n=17120 32.8(32.8);n=34240 32.7(32.8);n=34240 3	Chronic obstructive pulmonary disease	466(1.10%)	122(0.71%)	344(1.37%)	0.07	243(0.70%)	122(0.71%)	121(0.70%)	<0.01
diabetic drugs 9.5(26.7);n=42129 12.7(32.8);n=17120 7.3(21.3);n=25009 0.2 12.7(32.8);n=34240 12.7(32.8);n=17120 12.8(32.7);n=17120 <0.01	Medications								
Sulphonylurea 32456(77.03%) 12393(72.38%) 20063(80.22%) 0.19 26040(76.05%) 12393(72.38%) 13647(79.71%) 0.17* Insulin 21040(49.94%) 8455(49.38%) 12585(50.32%) 0.02 16773(48.98%) 8455(49.38%) 8318(48.58%) 0.02 Acarbose 1402(3.32%) 640(3.73%) 762(3.04%) 0.04 1235(3.60%) 640(3.73%) 595(3.47%) 0.01 Thiazolidinedione 8506(20.19%) 4448(25.98%) 4058(16.22%) 0.24* 8131(23.74%) 4448(25.98%) 3683(21.51%) 0.11* Glucagon-like peptide-1 receptor 2666(6.32%) 1159(6.76%) 1507(6.02%) 0.03 2250(6.57%) 1159(6.76%) 1091(6.37%) 0.02 agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01	Number of anti- diabetic drugs	9.5(26.7);n=42129	12.7(32.8);n=17120	7.3(21.3);n=25009	0.2	12.7(32.8);n=34240	12.7(32.8);n=17120	12.8(32.7);n=17120	<0.01
Insulin 21040(49.94%) 8455(49.38%) 12585(50.32%) 0.02 16773(48.98%) 8455(49.38%) 8318(48.58%) 0.02 Acarbose 1402(3.32%) 640(3.73%) 762(3.04%) 0.04 1235(3.60%) 640(3.73%) 595(3.47%) 0.01 Thiazolidinedione 8506(20.19%) 4448(25.98%) 4058(16.22%) 0.24* 8131(23.74%) 4448(25.98%) 3683(21.51%) 0.11* Glucagon-like peptide-1 receptor 2666(6.32%) 1159(6.76%) 1507(6.02%) 0.03 2250(6.57%) 1159(6.76%) 1091(6.37%) 0.02 agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12	Metformin	37650(89.36%)	15922(93.00%)	21728(86.88%)	0.20*	31909(93.19%)	15922(93.00%)	15987(93.38%)	0.02
Acarbose 1402(3.32%) 640(3.73%) 762(3.04%) 0.04 1235(3.60%) 640(3.73%) 595(3.47%) 0.01 Thiazolidinedione 8506(20.19%) 4448(25.98%) 4058(16.22%) 0.24* 8131(23.74%) 4448(25.98%) 3683(21.51%) 0.11* Glucagon-like peptide-1 receptor 2666(6.32%) 1159(6.76%) 1507(6.02%) 0.03 2250(6.57%) 1159(6.76%) 1091(6.37%) 0.02 agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	Sulphonylurea	32456(77.03%)	12393(72.38%)	20063(80.22%)	0.19	26040(76.05%)	12393(72.38%)	13647(79.71%)	0.17*
Thiazolidinedione 8506(20.19%) 4448(25.98%) 4058(16.22%) 0.24* 8131(23.74%) 4448(25.98%) 3683(21.51%) 0.11* Glucagon-like peptide-1 receptor 2666(6.32%) 1159(6.76%) 1507(6.02%) 0.03 2250(6.57%) 1159(6.76%) 1091(6.37%) 0.02 agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	Insulin	21040(49.94%)	8455(49.38%)	12585(50.32%)	0.02	16773(48.98%)	8455(49.38%)	8318(48.58%)	0.02
Glucagon-like peptide-1 receptor 2666(6.32%) 1159(6.76%) 1507(6.02%) 0.03 agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	Acarbose	1402(3.32%)	640(3.73%)	762(3.04%)	0.04	1235(3.60%)	640(3.73%)	595(3.47%)	0.01
peptide-1 receptor 2666(6.32%) 1159(6.76%) 1507(6.02%) 0.03 2250(6.57%) 1159(6.76%) 1091(6.37%) 0.02 agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	Thiazolidinedione	8506(20.19%)	4448(25.98%)	4058(16.22%)	0.24*	8131(23.74%)	4448(25.98%)	3683(21.51%)	0.11*
agonists Statins and fibrates 26683(63.33%) 12716(74.27%) 13967(55.84%) 0.39* 25225(73.67%) 12716(74.27%) 12509(73.06%) 0.03 ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	Glucagon-like								
ACEI/ARB 22307(52.94%) 10563(61.69%) 11744(46.95%) 0.30* 21120(61.68%) 10563(61.69%) 10557(61.66%) <0.01 Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	peptide-1 receptor agonists	2666(6.32%)	1159(6.76%)	1507(6.02%)	0.03	2250(6.57%)	1159(6.76%)	1091(6.37%)	0.02
Diuretics 12276(29.13%) 5536(32.33%) 6740(26.95%) 0.12 11411(33.32%) 5536(32.33%) 5875(34.31%) 0.04	Statins and fibrates	26683(63.33%)	12716(74.27%)	13967(55.84%)	0.39*	25225(73.67%)	12716(74.27%)	12509(73.06%)	0.03
	ACEI/ARB	22307(52.94%)	10563(61.69%)	11744(46.95%)	0.30*	21120(61.68%)	10563(61.69%)	10557(61.66%)	<0.01
Beta-blockers 11878(28.19%) 5048(29.48%) 6830(27.31%) 0.05 10565(30.85%) 5048(29.48%) 5517(32.22%) 0.06	Diuretics	12276(29.13%)	5536(32.33%)	6740(26.95%)	0.12	11411(33.32%)	5536(32.33%)	5875(34.31%)	0.04
	Beta-blockers	11878(28.19%)	5048(29.48%)	6830(27.31%)	0.05	10565(30.85%)	5048(29.48%)	5517(32.22%)	0.06

Calcium channel blockers (dihydropyridine)	21531(51.10%)	9919(57.93%)	11612(46.43%)	0.23*	19921(58.18%)	9919(57.93%)	10002(58.42%)	0.01
Calcium channel								
blocker (non-	11656(27.66%)	5014(29.28%)	6642(26.55%)	0.06	9795(28.60%)	5014(29.28%)	4781(27.92%)	0.03
dihydropyridine)	,	(,	(, , , , , , , , , , , , , , , , , , , ,	(- (
Systemic steroids	269(0.63%)	126(0.73%)	143(0.57%)	0.02	252(0.73%)	126(0.73%)	126(0.73%)	<0.01
Antiplatelets	13825(32.81%)	6401(37.38%)	7424(29.68%)	0.16	12869(37.58%)	6401(37.38%)	6468(37.78%)	0.01
Alpha-blockers	7488(17.77%)	2624(15.32%)	4864(19.44%)	0.11	5033(14.69%)	2624(15.32%)	2409(14.07%)	0.04
Aspirin	12408(29.45%)	5963(34.83%)	6445(25.77%)	0.2	11902(34.76%)	5963(34.83%)	5939(34.69%)	<0.01
Calculated biomarker	` '	,	, ,		, , ,	,	, ,	
Abbreviated MDRD, mL/min/1.73m^2	80.8(26.9);n=34221	88.6(22.6);n=14077	75.4(28.3);n=20144	0.51*	87.5(23.2);n=28366	88.6(22.6);n=14077	86.4(23.7);n=14289	0.09
Renal function tests								
Creatinine, umol/L	103.7(79.5);n=34221	87.9(29.0);n=14077	114.8(99.2);n=20144	0.37*	89.7(37.2);n=28366	87.9(29.0);n=14077	91.4(43.8);n=14289	0.09
Lipid tests								
Triglyceride, mmol/L	1.7(1.8);n=32353	1.9(2.0);n=13493	1.7(1.6);n=18860	0.1	1.9(2.0);n=27134	1.85(1.96);n=13493	1.87(2.08);n=13641	0.01
Low-density lipoprotein, mmol/L	2.4(0.8);n=31726	2.3(0.8);n=13219	2.4(0.8);n=18507	0.04	2.4(0.8);n=26546	2.3(0.8);n=13219	2.4(0.8);n=13327	0.05
High-density lipoprotein, mmol/L	1.1(0.3);n=32298	1.09(0.28);n=13468	1.14(0.31);n=18830	0.14	1.1(0.3);n=27093	1.09(0.28);n=13468	1.1(0.29);n=13625	0.04
Total cholesterol, mmol/L	4.2(1.0);n=32387	4.22(1.01);n=13510	4.23(0.99);n=18877	0.01	4.3(1.0);n=27166	4.2(1.0);n=13510	4.3(1.0);n=13656	0.06
Glucose tests								
Haemoglobin A1C, %	8.1(1.6);n=33538	8.3(1.6);n=13824	8.0(1.6);n=19714	0.18	8.3(1.6);n=27789	8.25(1.61);n=13824	8.26(1.58);n=13965	0.01
Fasting glucose, mmol/L	9.0(3.9);n=30477	9.2(3.6);n=12691	8.8(4.2);n=17786	0.08	9.2(3.8);n=25612	9.2(3.6);n=12691	9.3(4.1);n=12921	0.04

Table 2. Incidence rate (IR) per 1000 person-year of new onset prostate cancer, cancerrelated mortality, and all-cause mortality in the cohort before and after 1:1 propensity score matching.

SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor; MDRD: modification of diet in renal disease

Adjusted for significant demographics, past comorbidities, duration of diabetes mellitus, number of prior hospitalizations, number of anti-diabetic drugs, non-SGLT2I/DPP4I medications, abbreviated MDRD, HbA1c, fasting glucose.

Prostate	Number of	Number	Total	Follow-up	Incidence	Adjusted	P-value
cancer	patients	of events	person-	duration, years	[95% CI]	hazard ratio	
			year	[95% CI]		[95% CI]	
DPP4I	17120	102	92074.6	5.6 [5.31-5.83]	1.11[0.90-	1 [reference]	NA
					1.34]		
SGLT2I	17120	60	94794.8	5.62 [5.35-5.83]	0.63[0.48-	0.45[0.30-0.70]	0.0003
					0.81]		
Cancer-	Number of	Number	Total	Follow-up	Incidence	Adjusted	P value
related	patients	of events	person-	duration, years	[95% CI]	hazard ratio	
mortality			year	[95% CI]		[95% CI]	
DPP4I	17120	260	92299.7	5.6 [5.31-5.83]	2.81[2.48-	1 [reference]	NA
					3.18]		
SGLT2I	17120	99	94892.2	5.62 [5.33-5.82]	1.04[0.85-	0.57[0.40-0.76]	<0.0001
					1.27]		
All-cause	Number of	Number	Total	Follow-up	Incidence	Adjusted	P value
mortality	patients	of events	person-	duration, years	[95% CI]	hazard ratio	
			year	[95% CI]		[95% CI]	
DPP4I	17120	1652	92299.7	5.6 [5.31-5.83]	17.9[17.0-	1 [reference]	NA
					18.8]		
SGLT2I	17120	E 4.1	94892.2	5.62 [5.35-5.82]	5.70[5.23-	0.68[0.46-0.78]	< 0.0001
		541			6.20]		